Email Benjamin_sk_ong@moh.gov.sg

Benjamin is Director (MOCA) at the Agency for Care Effectiveness (ACE), Ministry of Health. In this capacity, he leads strategic oversight across economic modelling, utilisation review and outcomes evaluation, consumer engagement and education, horizon scanning and health technology adoption functions, directing cross-functional teams to support national health technology assessment (HTA) programme. His work informs subsidy decisions for drugs, vaccines, gene therapies, and medical technologies through economic evaluations and real-world data analyses, while also championing patient involvement in HTA and the development of consumer-facing health resources.

Benjamin began his healthcare career as a pharmacist at the National University Hospital Singapore, before serving as Deputy Director at the Health Sciences Authority, bringing both clinical and regulatory foundation to his policy work. Regionally, he is the immediate past President and Board member of HTAsiaLink, a network of organizational and individual members who are involved in HTA research and evidence-based policy decision-making in Asia and Pacific region, Benjamin plays a key role in fostering capacity building and regional collaboration in healthcare decision-making.

• NUS Saw Swee Hock School of Public Health
• Ministry of Health Singapore
• HTAsiaLink network

• Master of Science (Epidemiology), London School of Hygiene and Tropical Medicine | 2009 – 2011
• Bachelor of Science (Pharmacy) (First Class Honors), National University of Singapore | 1997-2001

• Director (MOCA), Agency for Care Effectiveness | Nov 2025 – Present
• Head, Agency for Care Effectiveness | Apr 2025 – Oct 2025
• Senior Principal Lead Specialist, Agency for Care Effectiveness | Apr 2023 – Mar 2025
• Senior Lead Specialist, Agency for Care Effectiveness | May 2020 – Mar 2023
• Board Member, HTAsiaLink | Sep 2022 – Present
• President, HTAsiaLink | Sep 2023 – Aug 2025
• Deputy Director, Scientific Advisory & International Engagement, Health Sciences Authority | Apr 2016 – Apr 2020
• Deputy Director, Pharmacoeconomics & Drug Utilisation, Health Sciences Authority | Apr 2013 – Mar 2016
• Senior Specialist, Pharmacoeconomics & Drug Utilisation, Health Sciences Authority | Oct 2007 – Mar 2013
• Senior Pharmacist, National University Hospital | Jan 2001 – Sep 2007

• Director (MOCA), ACE, MOH

• Zhao YJ, Khoo AL, Tan G, Teng M, Tee C, Tan BH, Ong B, Lim BP, Chai LYI. Network Meta-analysis and Pharmacoeconomic Evaluation of Fluconazole, Itraconazole, Posaconazole, and Voriconazole in Invasive Fungal Infection Prophylaxis. Antimicrob Agents Chemother. 2015;60(1):376-386. Published 2015 Nov 2. doi:10.1128/AAC.01985-15
• Elizabeth E Roughead, Dong-Sook Kim, Benjamin Ong & Anna Kemp-Casey. (‎2018)‎. Pricing policies for generic medicines in Australia, New Zealand, the Republic of Korea and Singapore: patent expiry and influence on atorvastatin price. WHO South-East Asia Journal of Public Health, 7 (‎2)‎, 99 – 106. World Health Organization. Regional Office for South-East Asia. https://apps.who.int/iris/handle/10665/329581
• Goh, L.G.H., Sun, J., Ong, B.S.K. et al. Real-world evaluation of sodium-glucose co-transporter-2 inhibitors and dipeptidyl peptidase-4 inhibitors for managing type 2 diabetes mellitus: a retrospective multi-ethnic cohort study. J Diabetes Metab Disord (2022). https://doi.org/10.1007/s40200-022-01004-4
• Tan, C.-K., Luo, X.-S., Ong, B.S.-K., Lin, L. and Ng, K.-H. (2022), Real-world impact of a subsidy decision of sofosbuvir–velpatasvir for treatment of chronic hepatitis C on clinical practice and patient outcomes. JGH Open. https://doi.org/10.1002/jgh3.12850
• Boon Piang Cher, Sharon Goh, Mohamed Ismail Abdul Aziz, Grace Wong, Raymond Ng Chee Hui, Benjamin Shao-Kiat Ong & Kwong-Hoe Ng (2024) Cost-utility analysis of sacituzumab govitecan versus chemotherapy for the treatment of metastatic triple-negative breast cancer in Singapore, Expert Review of Pharmacoeconomics & Outcomes Research, 24:2, 217-225, DOI: 10.1080/14737167.2023.2291155
• She Hui Tan, Louise Gek Huang Goh, Benjamin Shao Kiat Ong, Darren Sze Guan Ng, Liang Lin, Raymond Chee Hui Ng, Bernard Yu‑Hor Thong, Kwong Ng (2024). Impact of Value-driven Healthcare Strategies to Optimise Biosimilar Use: The Singapore Story. PharmacoEconomics – Open, https://doi.org/10.1007/s41669-024-00491-w
• Sitanggang RJ, Chavarina KK, K.C. S, … Benjamin Shao Kiat Ong et al. Impact of COVID-19 pandemic on HTAsiaLink network members. International Journal of Technology Assessment in Health Care. 2024;40(1):e63. doi:10.1017/S0266462324000357
• Wong, W. H. M., Ng, R., Aziz, M. I. A., Ong, B. S. K., & Ng, K. (2025). Cost-effectiveness analysis of trastuzumab emtansine for second-line treatment of HER2+ advanced breast cancer in Singapore. Expert Review of Pharmacoeconomics & Outcomes Research, 1–9. https://doi.org/10.1080/14737167.2025.2456065
• Surendra, Naren Kumar, Jiamin Ong, Xin Yi Wong, Michelle Poon, Lydia Loke, Liang Lin, Mohamed Ismail Abdul Aziz, Benjamin Shao Kiat Ong, and Kwong Ng. 2025. “Cost-Effectiveness of Ruxolitinib in Singapore for Patients with Chronic Graft-versus-Host Disease.” Expert Review of Pharmacoeconomics & Outcomes Research, July, 1–8. doi:10.1080/14737167.2025.2529366.
• Sitanggang RJ, Pongcharoenyong L, Kongkam N, … Ong BSK et al. Charting the way forward for HTA in Asia-Pacific: HTAsiaLink’s strategic plan. International Journal of Technology Assessment in Health Care. 2025;41(1):e87
• Yot Teerawattananon, Yi Wang, Sarin KC, Hugo C. Turner, Benjamin SK Ong & Wanrudee Isaranuwatchai. Harnessing health economic evaluation for policy and practice. Communications Medicine (2026) 6: 234